Fortis Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Fortis Capital Advisors's BMY Position: Q1 2026 in Review
Fortis Capital Advisors increased its Bristol-Myers Squibb (BMY) stake by 25% in Q1 2026, buying an estimated $143K and bringing the position to 12,042 shares worth $730K. The position accounts for 0.1% of the portfolio, ranked #186.
Fortis Capital Advisors first reported a position in BMY in Q4 2022 and has held it in 5 quarters since. The position peaked at $1.21M in Q1 2025. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Fortis Capital Advisors held 12,042 shares of Bristol-Myers Squibb worth $730K as of Q1 2026.
- Fortis Capital Advisors bought 2,446 Bristol-Myers Squibb shares in Q1 2026, an estimated $143K.
- Bristol-Myers Squibb made up 0.1% of Fortis Capital Advisors's portfolio in Q1 2026, its #186 holding.
- Fortis Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 5 quarters since.
- Fortis Capital Advisors's Bristol-Myers Squibb position peaked at $1.21M in Q1 2025.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Fortis Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.